A Phase 2/3 interventional study of Treprostinil Palmitil Inhalation Powder and Placebo in Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Insmed Incorporated. Completed at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Insmed Incorporated · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Hypertension, Pulmonary with a site in Germany — 21 open to participants now, 28 under way, 6 of them phase 3. Hypertension, Pulmonary · Germany.
Among the 150 studies in Hypertension, Pulmonary with a site in Germany, this one is the 81st largest by enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 2/3, and was the 131st registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →21 of the 150 studies in Hypertension, Pulmonary with a site in Germany are open now. Recruiting first, the newest first:
Insmed Incorporated · Sites in Germany, United States, Czechia and 5 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
Liquidia Technologies, Inc. · Sites in Germany, United States, Australia and 9 more countries
Ages 18–80
Insmed Incorporated · Sites in Germany, United States, Argentina and 27 more countries
Ages 18+
AllRock Bio, Inc. · Sites in Germany, United States, Australia and 6 more countries
Ages 18–80
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 40 · Phase 3 39 · Phase 4 2
First in 1993; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 86 across the 105 interventional studies, 394 across the 44 observational. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 150 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 5 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
6 of the studies in Hypertension, Pulmonary with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06616974Tectonic TherapeuticA Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | 2026-11-24 |
| NCT05903001RWTH Aachen UniversityDiaphragmatic Function as a Biomarker | 2026-12-30 |
| NCT01347216Technische Universität DresdenCOMPERA / COMPERA-KIDS | 2026-12-31 |
| NCT07175038AllRock Bio, Inc.A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 150 studies in Hypertension, Pulmonary with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant or breastfeeding. Male and female participants must use that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants of must have a negative urine pregnancy test result at trial entry before the first dose of study drug.
- Any medical or psychological condition, including relevant laboratory abnormalities at screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease that may present an unreasonable risk to the study participant as a result of participation in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are not transitioning immediately from INS1009-211 and other lead-in studies, will be administered TPIP, once daily (QD), during 3-week titration period. Participants who are transitioning immediately from a randomized blinded lead-in TPIP study and who previously received: 1. TPIP- will be administered placebo QD along with the maximum tolerated dose (MTS) TPIP dose from lead-in study in a blinded manner during 3-week titration period. 2. Placebo- will be administered TPIP QD along with the achieved placebo dose from lead-in study in a blinded manner during 3-week titration period. The overall treatment period will be 24 months.
Drug: Treprostinil Palmitil Inhalation Powder · Drug: Placebo
Oral inhalation using a capsule-based dry powder inhaler device.
Also known as: INS1009
Oral placebo inhalation using a capsule-based dry powder inhaler device.
Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)
Time frame: Up to approximately 25 months
Absolute Change From Pre-Open-Label Extension (OLE) Baseline in 6-Minute Walk Distance (6MWD)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Relative Change From Pre-OLE Baseline in 6-MWD
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in Forced Vital Capacity (FVC)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in Percent Predicted FVC (FVC%)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in Percent Predicted FEV1 (FEV1%)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Change From Pre-OLE Baseline in Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity (FEF25-75%)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Absolute Change From Pre-OLE Baseline in Lung Diffusion Capacity for Carbon Monoxide (DLCO)
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 12 and 24
Relative Change From Pre-OLE Baseline in Lung DLCO
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 12 and 24
Change From Pre-OLE Baseline in the Concentration of N-Terminal Fragment B-Type Natriuretic Peptide (NT-proBNP) in Blood
Time frame: Pre-OLE Baseline (Baseline of the lead-in TPIP study) to Months 6, 12, 18, and 24
Annualized Rate of Clinical Worsening Events Based on Percentage of Participants With Clinical Worsening Events
Clinical worsening events are defined as one of the following: Hospitalization due to a cardiopulmonary indication; Lung transplantation; Death from any cause; Decrease in 6MWD ≥ 15% from baseline; Directly related to disease under study, at 2 consecutive visits at least 24 hours apart; Need for additional pulmonary hypertension (PH) therapy. Annualized clinical worsening event rate is defined as the total number of clinical worsening events that occurred during the treatment period divided by the total number of participant-years during the treatment period.
Time frame: Up to Month 24
Annualized Rate of Occurrence of Acute Exacerbations of Underlying Interstitial Lung Disease (AE-ILDs)
Time frame: Up to Month 24
Change From OLE Baseline in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Score
Time frame: OLE Baseline (Day 1) to Months 6, 12, 18, and 24
Change From OLE Baseline in the Euro Quality of Life-5 Dimension-5 Level (EQ-5D-5L) Questionnaire Score
Time frame: OLE Baseline (Day 1) to Months 6, 12, 18, and 24
Plasma Concentration Levels of Treprostinil Palmitil (TP) and Treprostinil (TRE)
Time frame: OLE Baseline (Day 1), Months 6, 12, 18, and 24
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Apr 2026, 34 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil hexadecyl ester